Trials / Completed
CompletedNCT00839176
Efficacy Study of RX-10100 to Treat Major Depressive Disorder (MDD)
A Double-blinded, Randomized, Placebo-controlled, Dose-Exploring Study of RX-10100 When Given for Eight Consecutive Weeks to Subjects With Major Depression Disorder (MDD)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Rexahn Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this Phase IIa trial is to determine the effective dose and treatment period for an upcoming RX-10100 Phase IIb trial in subjects with major depression disorder (MDD). The secondary objectives of this trial are to evaluate the safety and quality of life in subjects with MDD receiving RX-10100 treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RX-10100 | Extended-release tablet, 5\~15mg, twice day (morning \& evening) at least 30 min before meal, 8 weeks |
Timeline
- Start date
- 2009-01-01
- Primary completion
- 2009-09-01
- Completion
- 2009-10-01
- First posted
- 2009-02-09
- Last updated
- 2013-11-19
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00839176. Inclusion in this directory is not an endorsement.